These Bidding Rules Guide, Establish And Determine The Rules And Procedures By Which The Natural And Legal Persons Interested In Participating In The Call For Public Proposal For The Acquisition Of Rituximab Must Be Governed, For Patients Of The Dr. Hernán Henríquez Aravena Hospital, Hereinafter : “The Hospital.” These Bases Refer To The Conditions And Technical Characteristics Required For The Acquisition Of Rituximab, Hereinafter “The Medicine”, For A Validity Of Twenty-Four 24 Months. The Drug Is Used In Non-Hodgkins Lymphomas (Nhl) – Treatment Of Patients With Low-Grade Or Follicular Cd20-Positive B-Cell Non-Hodgkins Lymphoma (Nhl), Relapsed Or Chemoresistant. –Treatment Of Patients With Previously Untreated Stage Iii-Iv Follicular Lymphoma, In Association With Chemotherapy. –Maintenance Treatment Of Patients With Follicular Lymphoma Who Have Responded To Induction Treatment. –Treatment Of Patients With Cd20-Positive Diffuse Large B-Cell Non-Hodgkin Lymphoma, In Association With Chop Chemotherapy Cyclophosphamide, Doxorubicin, Vincristine And Prednisone. Chronic Lymphocytic Leukemia: Rituximab I.V. In Association With Chemotherapy It Is Indicated For The Treatment Of Patients With Previously Untreated Or Relapsed Refractory Chronic Lymphocytic Leukemia (Cll). Rheumatoid Arthritis: Rituximab I.V. In Association With Methotrexate It Is Indicated In Adult Patients For: -Treatment Of Moderately Or Severely Active Rheumatoid Arthritis That Has Not Responded Adequately To Disease-Modifying Antirheumatic Drugs Dmards, Including Methotrexate. -Treatment Of Moderate Or Severe Active Arthritis In Patients Who Have Not Responded Adequately To One Or More Anti-Tnf Tumor Necrosis Factor Inhibitors Or Do Not Tolerate Them. Rituximab Iv Has Been Shown To Reduce The Rate Of Progression Of Radiologically Determined Joint Damage And Improve Physical Function And Induce A Significant Clinical Response When Administered Concomitantly With Methotrexate. Adult And Pediatric Patients From 6 Years Of Age With Granulomatosis With Wegeners Polyangiitis Gpa And Microscopic Polyangiitis Pam: Rituximab I.V. In Combination With Glucocorticoids It Is Indicated For The Treatment Of Adult Patients With Highly Active Granulomatosis With Polyangiitis Gpa, Also Known As Wegeners Granulomatosis And Microscopic Polyangiitis Pam. Rituximab Iv In Combination With Glucocorticoids It Is Indicated For The Treatment Of Pediatric Patients 6 To 17 Years Of Age With Active Gpa Or Pam. According To What Is Required By The Technical Reference, Head Of Preparations Unit And Oncology Pharmacy Manager, A Stability Of 7 Seven Days Once Diluted Is Required As An Admissibility Requirement. This Stability Once Diluted Will Be Admissible If You Present A Resolution Granted By The Isp, Indicating This Stability In Detail And Indicating The Health Registration Number Of The Drug With Which You Are Applying. If This Stability Is Achieved At A Temperature Between 2 To 8°, You Must Apply With A Refrigerated Display Case, According To The Technical Specifications Annex N°2 B.
Dear Sir,
Warm Greetings from TenderDetail.com !!
We have received Tender Document request for the TDR No : 88747711
Tender Notice along with it's Attachments ( Tender Document / Scan Image of News Paper)
sent to your Email Address :.
Please check your email for Tender Document.
